Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

USA - NASDAQ:LXRX - US5288723027 - Common Stock

1.25 USD
-0.18 (-12.59%)
Last: 11/7/2025, 8:00:01 PM
1.24 USD
-0.01 (-0.8%)
After Hours: 11/7/2025, 8:00:01 PM
Fundamental Rating

3

LXRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. LXRX has a bad profitability rating. Also its financial health evaluation is rather negative. LXRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
In the past 5 years LXRX always reported negative net income.
LXRX had a negative operating cash flow in each of the past 5 years.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

The Return On Assets of LXRX (-53.47%) is comparable to the rest of the industry.
LXRX has a Return On Equity (-93.19%) which is in line with its industry peers.
Industry RankSector Rank
ROA -53.47%
ROE -93.19%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

Looking at the Gross Margin, with a value of 99.18%, LXRX belongs to the top of the industry, outperforming 97.75% of the companies in the same industry.
In the last couple of years the Gross Margin of LXRX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
The number of shares outstanding for LXRX has been increased compared to 5 years ago.
The debt/assets ratio for LXRX has been reduced compared to a year ago.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -9.99, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
LXRX has a worse Altman-Z score (-9.99) than 72.28% of its industry peers.
LXRX has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
LXRX has a Debt to Equity ratio of 0.43. This is in the lower half of the industry: LXRX underperforms 71.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -9.99
ROIC/WACCN/A
WACC9.44%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

LXRX has a Current Ratio of 4.16. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Current ratio (4.16) which is in line with its industry peers.
A Quick Ratio of 4.16 indicates that LXRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.16, LXRX is in line with its industry, outperforming 48.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.16
Quick Ratio 4.16
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

LXRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.67%, which is quite impressive.
LXRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 2481.48%.
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.29%

3.2 Future

The Earnings Per Share is expected to grow by 13.37% on average over the next years. This is quite good.
Based on estimates for the next years, LXRX will show a very strong growth in Revenue. The Revenue will grow by 73.16% on average per year.
EPS Next Y69.21%
EPS Next 2Y25.01%
EPS Next 3Y18.64%
EPS Next 5Y13.37%
Revenue Next Year355.96%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as LXRX's earnings are expected to grow with 18.64% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.01%
EPS Next 3Y18.64%

More info and screens

0

5. Dividend

5.1 Amount

LXRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (11/7/2025, 8:00:01 PM)

After market: 1.24 -0.01 (-0.8%)

1.25

-0.18 (-12.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners72.01%
Inst Owner Change-0.1%
Ins Owners0.86%
Ins Owner Change0.15%
Market Cap454.25M
Revenue(TTM)31.08M
Net Income(TTM)-120.62M
Analysts80
Price Target2.81 (124.8%)
Short Float %7.48%
Short Ratio11.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)71.13%
Min EPS beat(2)29.61%
Max EPS beat(2)112.65%
EPS beat(4)3
Avg EPS beat(4)41.42%
Min EPS beat(4)-7.28%
Max EPS beat(4)112.65%
EPS beat(8)7
Avg EPS beat(8)23.99%
EPS beat(12)9
Avg EPS beat(12)13.92%
EPS beat(16)13
Avg EPS beat(16)12.01%
Revenue beat(2)1
Avg Revenue beat(2)234.48%
Min Revenue beat(2)-12.42%
Max Revenue beat(2)481.39%
Revenue beat(4)2
Avg Revenue beat(4)182.32%
Min Revenue beat(4)-41.43%
Max Revenue beat(4)481.39%
Revenue beat(8)2
Avg Revenue beat(8)66.06%
Revenue beat(12)3
Avg Revenue beat(12)55.44%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20%
EPS NY rev (1m)0%
EPS NY rev (3m)50.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)266.92%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.77
P/FCF N/A
P/OCF N/A
P/B 3.51
P/tB 5.35
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.16
BVpS0.36
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.47%
ROE -93.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.18%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score6
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 129.52%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.16
Quick Ratio 4.16
Altman-Z -9.99
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)74.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y69.21%
EPS Next 2Y25.01%
EPS Next 3Y18.64%
EPS Next 5Y13.37%
Revenue 1Y (TTM)2481.48%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%710.29%
Revenue Next Year355.96%
Revenue Next 2Y4.9%
Revenue Next 3Y35.41%
Revenue Next 5Y73.16%
EBIT growth 1Y39.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.12%
EBIT Next 3Y13.3%
EBIT Next 5YN/A
FCF growth 1Y8.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.04%
OCF growth 3YN/A
OCF growth 5YN/A

LEXICON PHARMACEUTICALS INC / LXRX FAQ

What is the fundamental rating for LXRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to LXRX.


Can you provide the valuation status for LEXICON PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to LEXICON PHARMACEUTICALS INC (LXRX). This can be considered as Overvalued.


Can you provide the profitability details for LEXICON PHARMACEUTICALS INC?

LEXICON PHARMACEUTICALS INC (LXRX) has a profitability rating of 2 / 10.


What is the earnings growth outlook for LEXICON PHARMACEUTICALS INC?

The Earnings per Share (EPS) of LEXICON PHARMACEUTICALS INC (LXRX) is expected to grow by 69.21% in the next year.